17th Annual Meeting of the Japanese Society of Clinical
Neuropsychopharmacology

October 3-5, 2007
Osaka International House Foundation, Osaka, Japan

FIRST AUTHOR INDEX
First Name	Last Name	No.	Title
MIYAKE	Nobumi	O-02	Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidone.
Ishii	K	O-04	Efficacy and safety of twice a day administration of perospirone for patients with schizophrenia.
Nakane	Hideyuki	O-06	Validity and Safety of Olanzapine-Zydis to acute symptoms of schizophrenia – Nagasaki Zydis investigate group Final report –
Harada	Toshiki	O-08	Four cases of oral dyskinesia during quetiapine treatment
Isotani	Toshiaki	O-10	Evaluation of aripiprazole treatment for schizophrenic patients
Kosaka	Takamitsu	O-14	Efficacy of Supplemental food containing Guarana for cognitive functional disorder in schizophrenia.
Yoshimura	Reiji	O-19	Effects of SSRI or SNRI on blood levels of brain-derived neurotrophic factor and cytokines in depressed patients
Moritoki	Yukihiro	O-23	A case of OCD with prolonged aggressiveness and impulsivity apparently related to activation syndrome even after discontinuation of paroxetine
Yoshimura	Reiji	O-24	Effects of atypical antipsychotic drugs addition to antidepressants for refractory depression
Watanabe	Junzo	O-26	Effect of atypical antipsychotic agents on the QT interval: using ambulatory electrocardiographic (Holter) recording
Sukegawa	Tsuruhei	O-30	The relationship between the administration of antihypotensives and survival rate on inptients with schizophrenia
Sugita	Atsuko	O-31	Brain derived neurotrophic factor is associated with disease severity of neuropsychiatric systemic lupus erythematosus
Hokyo	Akira	O-39	The Clinical study of schizophrenia treatment by using the third generation antipsychotic; Aripiprazole
Hikaru Hori	Hikaru Hori	O-42	Effect of aripiprazole on plasma levels of catecholamine metabolites and brain-derived neurotriphic factor in schizophrenic patients
Fukui	Naoki	O-44	Association between D2 dopamine receptor gene polymorphism and extreme hyperprolactinemia induced by antipsychotics
Sawamura	Kazushi	O-46	Relationship between olanzapine-induced weight gain and SNP45T/G polymorphism in the adiponectin gene
Uchida	Naoki	O-48	Salivary cortisol and dehydroepiandrosterone in depressive patients
Suga	Hidemichi	O-49	A study of 1-year follow-up after ECT for patients with refractory depression.
Uemura	Keiichi	O-50	Efficacy and safety of low dose sulpiride treatment in patients with bipolar depression: A retrospective study
Jitsuiki	Hiroaki	O-51	Serum Valproate Levels in Maintenance Therapy for Bipolar Disorder in Japan
Umene	Wakako	O-53	Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham’s chorea
Shimizu	Yoshio	O-54	A case of specific phobia against her mother-in-law improved by paroxetine
Ota	Tomoo	O-55	Lithium (Li) augmentation to valproate (VPA) for paraneoplastic limbic encephalitis (PLE) with agitation: a case report.
Egami	Hideaki	O-56	Two adolescent cases of abnormal behavior to zolpidem administration
Ono	Hisae	P-02	A Study Examining Pharmacokinetics of Rapid Acting Intra-muscular Olanzapine in Japanese Agitated Patients with Schizophrenia
Ogino	Shin	P-03	Subjective Well-being in Schizophrenic Patients: A Four-group Comparison of Aripiprazole, Olanzapine, Risperidone, and Low-dose Haloperidol
Endo	Takako	P-04	Survey of Antipsychotic Medications Prescribed for Concomitant Use by Schizophrenia Patients Being Treated with Olanzapine
Kuramochi	Motoki	P-05	The efficacy and safety of olanzapine in acute schizophrenic patients : The interim analysis of a post marketing surveillance.
Yoshimura	N.	P-10	A comparison of efficacy and safety of risperidone,olanzapine,haloperidol and quetiapine for the treatment of acute agitation in patients with schizophrenia.
Hashimoto	Naoki	P-18	A 26 week outcome of the switching to the aripiprazole in 86 schizophrenia patients.
Kuramochi	Motoki	P-23	Effects of olanzapine on health outcome in patients with schizophrenia
Nishiuma	Shinichi	P-24	Final Report of the Postmarketing Prospective Study in Patients with Schzophrenia using Olanzapine
Kamei	Hiroyuki	P-27	Association between the severity of symptoms and illness insight/medication adherence in patients with schizophrenia
Utagawa	Itaru	P-28	Prescriptions Written for Schizophrenia Outpatients
Ono	Hisae	P-33	A Study Examining Pharmacokinetics of Rapid Acting Intra-muscular Olanzapine in Japanese Agitated Patients with Schizophrenia
Kikuyama	Hiroki	P-34	Effects of the serotonin transporter gene polymorphism on risperidone and perospirone efficacy and adverse events in schizophrenia.
Kanazawa	Tetsufumi	P-35	Effects of the DRD2 gene polymorphism on risperidone and perospirone efficacy and adverse events in schizophrenia.
Tsutsumi	Atsushi	P-36	Effects of the DRD4 gene polymorphism on risperidone and perospirone in schizophrenia.
Utsunomiya	Kensuke	P-39	No association between the dopamine D1 receptor gene (DRD1) polymorphism (-48A/G) and polydipsia in schizophrenia
Sakata	Shinichi	P-40	Association analysis between the HTR2A gene polymorphism (T102C) and polydipsia in schizophrenia
Shinkai	Takahiro	P-41	No association between TPH2 polymorphisms and polydipsia in schizophrenia
Inoue	Yoshiaki	P-43	Association analysis between the functional -485C>T polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia
Furuya	Motohide	P-47	Successful adjunctive treatment of Yi-Gan San for schizophrenia : A case report
Murata	Yusuke	P-50	Discontinuation Syndrome Associated with Paroxetine : A Clinical and Pharmacogenetic research
Takahashi	Hidetoshi	P-57	Effect of sertraline hydrochloride on prepulse inhibition and habituation of the acoustic startle startle reflex in patients with major depressive disorder; a preliminary study.
Okuda	Akiko	P-59	Necessity of early treatment of major depressive disorder.（The second report）-Prognosis and therapeutic response-
Yamada	Kazuo	P-60	New idea in the evidence-based guideline for treatment of bipolar depression in Japan
Kurumaji	Akeo	P-61	A clinical study of additive treatment with mood stabilizers on the inpatients with depressive disorders.
Iwamoto	Kunihiro	P-66	The effects of acute treatment with antidepressants on driving performance and cognitive function in healthy Japanese subjects
Wada	Ken	P-68	Two-year outcome of unipolar depression patients with manic or hypomanic switch during acute antidepressant treatment
Miyamoto	Ayumu	P-71	A patient with major depressive disorder combined with neuroleptic malignant syndrome caused by amoxapine
Naitoh	Hiroshi	P-75	Drug-induced hypersensitivity syndrome in a patient with bipolar II disorder on sodium valproate therapy.
Sawada	Masayuki	P-83	A case of adolescent patient with obsessive-compulsive disorder effectively treated by fluvoxamine and olanzapine
Kokubo	Yosuke	P-85	Drug treatment of panic disorder: the comparison between 1994-1996 and 2004-2006
Yoshida	Takafumi	P-86	Tandospirone augmentation of serotonin reuptake inhibitors for anxiety disorder: three cases
Shiozaki	Kazumasa	P-91	“Improvement of hallucination and delusion as BPSD after donepezil administration in a case with Alzheimer’s disease”
Kishimoto	Makiko	P-94	A case report of recurrent SSRI discontinuation syndrome with fasciculation and high CPK value
Endo	Go	P-95	A case of acute mandibular dystonia induced by concomitant administration of perospirone and clarithromycin
Obara	Yoshihiko	P-96	A case of nightmare improved markedly by risperidone
Hori	Hikaru	PA-1	Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients
Okugawa	Gaku	S1-4	Perospirone clinical comparison with risperidone
Miyamoto	Seiya	S1-5	Current position of aripiprazole and its future prospects
Okada	Takashi	S2-3	Pharmacotherapy for Children and Adolescents with Pervasive Developmental Disorders
Iida	Junzo	S2-4	Pharmacotherapy of children with Attention-Deficit/Hyperactivity Disorder
Suhara	Tetsuya	S3-2	Early Investigational New Drug for CNS using Positron Emission Tomography
Ishii	Ryouhei	S3-4	Source localizations of EEG oscillatory activity in association with plasma concentrations of antiepileptic drugs
Tajima	Osamu	S4-1	Pharmacologic Profile of Fluvoxamine and its Implication in the Treatment of Depression and Anxiety Disorders
Inoue	Takeshi	S4-3	Unique characteristics of sertraline
Sakamoto	Kaoru	S4-4	Proper Use of New Antidepressants – Focusing upon Differentiation between Milnacipran and SSRIs –
Honda	Mari	S5-4	Consideration of clinical trial with placebo: double-blind placebo-controlled trial for Schizophrenia